{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:01:05Z","timestamp":1789340465881,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100015733","name":"Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital","doi-asserted-by":"publisher","award":["10908, 10909, 11001, 11002, 11003, 11006, and 1101"],"award-info":[{"award-number":["10908, 10909, 11001, 11002, 11003, 11006, and 1101"]}],"id":[{"id":"10.13039\/501100015733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,1,16]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the survival impact of pre-concurrent chemoradiotherapy (CCRT) staging with positron emission tomography-CT (PET-CT) in patients with unresectable epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with unresectable stage IIIA\u2013IIIC EGFR mutation-positive adenocarcinoma undergoing definitive CCRT were divided into two groups: those who received PET-CT staging prior to CCRT and those with other staging methods. Survival outcomes were compared after propensity score matching.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Analysis of 11\u2009856 patients (5928 in each group) showed that PET-CT staging was associated with improved survival (adjusted HR of all-cause mortality: 0.74, 95%\u2009CI 0.71 to 0.79). Other prognostic factors included male sex, age group, clinical stage, adjuvant treatment, smoking status, Charlson Comorbidity Index score and treatment setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pre-CCRT staging with PET-CT in patients with unresectable EGFR mutation-positive adenocarcinoma of clinical stage IIIA\u2013IIIC was associated with enhanced survival. Independent prognostic factors were also identified.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thorax-2023-220702","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T18:50:47Z","timestamp":1707418247000},"page":"430-437","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic factors for survival in unresectable stage III EGFR mutation-positive lung adenocarcinoma: impact of pre-CCRT PET-CT"],"prefix":"10.1136","volume":"79","author":[{"given":"Wei-Chun","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Chang","family":"Shia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-558X","authenticated-orcid":false,"given":"Szu-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"2025032422450910000_79.5.430.1","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.3390\/jcm10204675","article-title":"Survival and treatment of lung cancer in Taiwan between 2010 and 2016","volume":"10","author":"Chang","year":"2021","journal-title":"J Clin Med"},{"key":"2025032422450910000_79.5.430.2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0720-OA"},{"key":"2025032422450910000_79.5.430.3","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000033"},{"key":"2025032422450910000_79.5.430.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1245"},{"key":"2025032422450910000_79.5.430.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23925"},{"key":"2025032422450910000_79.5.430.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"2025032422450910000_79.5.430.7","unstructured":"oncology NCpgi . NCCN clinical practice guidelines in oncology: non-small cell lung cancer. In: (NCCN) NCCN , ed. National Comprehensive Cancer Network (NCCN)Version 22023. Huntington, NY 11743: Harborside Press,LLC, 2023."},{"key":"2025032422450910000_79.5.430.8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/0971-3026.155831","article-title":"Imaging of lung cancer: Implications on staging and management","volume":"25","author":"Purandare","year":"2015","journal-title":"Indian J Radiol Imaging"},{"key":"2025032422450910000_79.5.430.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.10.044"},{"key":"2025032422450910000_79.5.430.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.06.034"},{"key":"2025032422450910000_79.5.430.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0875-1"},{"key":"2025032422450910000_79.5.430.12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00330-018-5764-9","article-title":"PET\/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients","volume":"29","author":"Lim","year":"2019","journal-title":"Eur Radiol"},{"key":"2025032422450910000_79.5.430.13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/RLU.0000000000004295","article-title":"Clinical effects of PET-CT before definite concurrent chemoradiotherapy in patients with unresectable stage IIIA-IIIB squamous cell carcinoma of the lungs","volume":"47","author":"Lin","year":"2022","journal-title":"Clin Nucl Med"},{"key":"2025032422450910000_79.5.430.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900043"},{"key":"2025032422450910000_79.5.430.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00132"},{"key":"2025032422450910000_79.5.430.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1468"},{"key":"2025032422450910000_79.5.430.17","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-181"},{"key":"2025032422450910000_79.5.430.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1785","article-title":"Neoadjuvant chemotherapy or endocrine therapy for invasive ductal carcinoma of the breast with high hormone receptor positivity and human epidermal growth factor receptor 2 negativity","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025032422450910000_79.5.430.19","unstructured":"Edition S , Edge S , Byrd D . AJCC cancer staging manual. J AJCC Cancer Staging Manual 2017."},{"key":"2025032422450910000_79.5.430.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543"},{"key":"2025032422450910000_79.5.430.21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hed.24763","article-title":"High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer","volume":"39","author":"Chang","year":"2017","journal-title":"Head Neck"},{"key":"2025032422450910000_79.5.430.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20671","article-title":"Assessment of predictive scoring system for 90-day mortality among patients with locally advanced head and neck squamous cell carcinoma who have completed concurrent chemoradiotherapy","volume":"3","author":"Lin","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025032422450910000_79.5.430.23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.radonc.2017.08.025","article-title":"Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma","volume":"125","author":"Chang","year":"2017","journal-title":"Radiother Oncol"},{"key":"2025032422450910000_79.5.430.24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.08.016","article-title":"Definitive radiotherapy or surgery for early oral squamous cell carcinoma in old and very old patients: a propensity-score-matched, nationwide, population-based cohort study","volume":"151","author":"Liu","year":"2020","journal-title":"Radiother Oncol"},{"key":"2025032422450910000_79.5.430.25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2018.03.007","article-title":"Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment","volume":"129","author":"Yen","year":"2018","journal-title":"Radiother Oncol"},{"key":"2025032422450910000_79.5.430.26","doi-asserted-by":"crossref","first-page":"110438","DOI":"10.1016\/j.jclinane.2021.110438","article-title":"Long-term analgesic and opioid prescription after surgery under general or neuraxial anesthesia: a retrospective nationwide sampling study","volume":"75","author":"Yu","year":"2021","journal-title":"J Clin Anesth"},{"key":"2025032422450910000_79.5.430.27","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.athoracsur.2015.05.100","article-title":"Pathologic upstaging in patients undergoing resection for stage I non-small cell lung cancer: are there modifiable predictors?","volume":"100","author":"Bott","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"2025032422450910000_79.5.430.28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lungcan.2021.03.017","article-title":"Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: a pooled analysis from five international centres","volume":"155","author":"Bissonnette","year":"2021","journal-title":"Lung Cancer"},{"key":"2025032422450910000_79.5.430.29","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"2025032422450910000_79.5.430.30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1148\/radiol.212798","article-title":"Use of preoperative FDG PET\/CT and survival of patients with resectable non-small cell lung cancer","volume":"305","author":"Chen","year":"2022","journal-title":"Radiology"},{"key":"2025032422450910000_79.5.430.31","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025032422450910000_79.5.430.32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1148\/rg.2019180061","article-title":"Recognizing radiation therapy-related complications in the chest","volume":"39","author":"Benveniste","year":"2019","journal-title":"Radiographics"},{"key":"2025032422450910000_79.5.430.33","doi-asserted-by":"crossref","DOI":"10.1186\/2049-6958-8-21","article-title":"Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis","volume":"8","author":"Yin","year":"2013","journal-title":"Multidiscip Respir Med"},{"key":"2025032422450910000_79.5.430.34","doi-asserted-by":"crossref","first-page":"100659","DOI":"10.1016\/j.ctarc.2022.100659","article-title":"Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer","volume":"33","author":"Aredo","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"2025032422450910000_79.5.430.35","doi-asserted-by":"crossref","unstructured":"Nassar A , Adib E , Feng J , et al . EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).. ASCO 2023. doi:10.1200\/JCO.2023.41.16_suppl.8567","DOI":"10.1200\/JCO.2023.41.16_suppl.8567"},{"key":"2025032422450910000_79.5.430.36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/1759-7714.14237","article-title":"Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors","volume":"13","author":"Wang","year":"2022","journal-title":"Thorac Cancer"},{"key":"2025032422450910000_79.5.430.37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025032422450910000_79.5.430.38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.02.004","article-title":"Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation","volume":"88","author":"Fukuhara","year":"2015","journal-title":"Lung Cancer"},{"key":"2025032422450910000_79.5.430.39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12890-020-1160-8","article-title":"Smoking is associated with pneumonia development in lung cancer patients","volume":"20","author":"Heo","year":"2020","journal-title":"BMC Pulm Med"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-220702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T06:07:07Z","timestamp":1742882827000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-220702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,15]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/thorax-2023-220702"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-220702","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}